Volitionrx Ltd (VNRX) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Volitionrx Ltd (VNRX) stock forecast summary
On Oct. 16, 2026, VNRX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Volitionrx Ltd is a small-cap company with a market capitalization of $2M. It ranks number 17 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its Current Ratio of 0.30x is the lowest of the 16 peers that report one.
For VNRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 37.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 50.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VNRX included.
Follow VNRX freeVNRX price chart and AI forecast
How VNRX ranks among 5172 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Volitionrx Ltd (VNRX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
Valuation & Market
| Metric | VNRX | Rank |
|---|---|---|
| Market Cap | $2M | 17/17 |
| EPS | $-1.01 | – |
| Revenue/Share | $0.18 | – |
| FCF/Share | $-1.43 | – |
Profitability & Margins
| Metric | VNRX | Rank |
|---|---|---|
| Operating Margin | -790.2% | 10/14 |
| EBT Margin | -790.2% | 10/14 |
Financial Health
| Metric | VNRX | Rank |
|---|---|---|
| Current Ratio | 0.30x | 16/16 |
| Interest Coverage | -35.5x | 10/14 |
| Working Capital | -$9M | 16/16 |
Cash Flow
| Metric | VNRX | Rank |
|---|---|---|
| Operating Cash Flow | -$20M | 11/16 |
| Free Cash Flow | -$20M | 6/10 |
| Capital Spending | -$20K | 1/10 |
| FCF/Sales | -796.8% | 7/10 |
| CapEx/Sales | 0.9% | 10/10 |
Operational Efficiency
| Metric | VNRX | Rank |
|---|---|---|
| Asset Turnover | 0.30x | 7/12 |
| Receivables Turnover | 8.9x | 2/11 |
| Fixed Assets Turnover | 0.7x | 9/12 |
| Days Sales Outstanding | 41 days | 10/11 |
Income Statement
| Metric | VNRX | Rank |
|---|---|---|
| Total Revenue | $2M | 9/12 |
| Operating Income | -$19M | 10/15 |
| R&D Expense | $9M | 10/16 |
| SG&A Expense | $18M | 8/12 |
Dividend & Shareholder Information
| Metric | VNRX | Rank |
|---|---|---|
| Shares Outstanding | 14M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $4M | |
| Cash & Short-term Investments | $3M | |
| Accounts Receivable | $280K | |
| Total Liabilities | $42M | |
| Short-term Debt | $10M |
VNRX quarterly financials and insider trading
Volitionrx Ltd (VNRX) industry peers
Companies classified under the same SEC industry code as Volitionrx Ltd (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| VNRX Volitionrx Ltd | ▶ | $2M |
| IDXX Idexx Laboratories Inc /De | ▼ | $44.15B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.51B |
| NEOG Neogen Corp | ▲ | $2.58B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.16B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.60B |
| QDEL Quidelortho Corp | ▲ | $885M |
| ACHV Achieve Life Sciences, Inc. | ▲ | $657M |
| MYGN Myriad Genetics Inc | ▲ | $381M |
| TKNO Alpha Teknova, Inc. | ▲ | $380M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▼ | $98M |
| AWHL Aspira Women's Health Inc. | ▲ | $11M |
| BMRA Biomerica Inc | ▲ | $9M |
| TRIB Trinity Biotech Plc | ▶ | $7M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▲ | $5M |
| QCLS Q/C Technologies, Inc. | ▼ | $4M |
Where VNRX sits on the market map
Volitionrx Ltd (VNRX) stock news
Loading...
Volitionrx Ltd (VNRX) stock forecast FAQ
What is the Volitionrx Ltd (VNRX) stock forecast?
On Oct. 16, 2026, VNRX is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Volitionrx Ltd stock predictions?
For VNRX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 37.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 50.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Volitionrx Ltd forecasts updated?
Volitionrx Ltd forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Volitionrx Ltd's industry peers?
17 issuers in our coverage, VNRX included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.